Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease

NCT03141944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2021-03-29

No results posted yet for this study

Summary

The objective of this study is to describe the evolution of hypodopaminergic syndrome in patients with Parkinson's disease.

Conditions

  • Parkinson Disease
  • Apathy

Interventions

OTHER

Starkstein scale of Apathy

The degree of apathy will be evaluated with the "Starkstein scale of Apathy"

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Anna CASTRIOTO, MD · University Hospital, Grenoble

Eligibility

Min Age
33 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-23
Primary Completion
2020-03-11
Completion
2020-03-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03141944 on ClinicalTrials.gov